Dementia with Lewy bodies: Clinical features and treatment

Drugs and Aging

Volumn 18, Issue 6, 2001, Pages 397-407

  Campbell, S ^a   Stephens, S ^a   Ballard, C ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; LEVODOPA; NEUROLEPTIC AGENT; RIVASTIGMINE; TACRINE;

COGNITIVE DEFECT; DEMENTIA; HUMAN; LEWY BODY; PARKINSONISM; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0035015457     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118060-00002     Document Type: Review

References (55)

1. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB)
2. Diffuse Lewy body disease, clinical features in 15 cases
3. The Lewy body variant of Alzheimer's disease: A clinical and pathological entity
4. A clinically and pathologically distinct form of Lewy body dementia in the elderly
5. Operational criteria for senile dementia of Lewy body type
6. An evaluation of the predictive validity & inter-rater reliability of clinical diagnostic criteria for SDLT
7. Non-cognitive symptoms in dementia with Lewy bodies
8. Clinical and neuropathological findings in Lewy body dementia
9. Psychiatric features in diffuse Lewy body disease: Findings in 28 pathologically diagnosed cases
10. Alzheimer's disease and its Lewy body variant: A clinical analysis of post-mortem verified cases
11. Hallucinations and signs of parkinsonism help distinguish patients with Alzheimer's disease at presentation: A clinicopathological study
12. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
13. Idiopathic clouding of consciousness - Do the patients have cortical Lewy body disease?
14. What is the clinical prevalence of Lewy body dementia?
15. One year follow up of parkinsonism in dementia with Lewy bodies
16. Motor and cognitive function in Lewy body dementia: Comparison with Alzheimer's and Parkinson's diseases
17. The prevalence, assessment and association of falls in dementia with Lewy bodies and Alzheimer's disease
18. The clinician assessment of fluctuation and the one day fluctuation assessment scale: Two methods to assess fluctuating confusion in dementia
19. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia
20. Acetylcholine in mind: A neurotransmitter correlate of consciousness
21. Dementia with Lewy bodies: Response of delirium-like features to donepezil
22. Psychotic symptoms and behavioural disturbances in dementia: A review
23. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptic use in dementia
24. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
25. Neuroleptic sensitivity to risperidone in Lewy body dementia
26. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease
27. Clinical diagnosis with Lewy bodies in a Japanese dementia registry
28. Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease; and in relation to neuroleptic medication
29. Neuropsychological deficits associated with diffuse Lewy body disease
30. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies
31. Evidence of a monoaminergic cholinergic imbalance related to visual hallucinations in Lewy body dementia
32. Cholinergic therapy and Lewy body dementia
33. Distinct profiles of neuropsychological impairment in dementia with Lewy bodies and Alzheimer's disease
34. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease
35. Lewy bodies and response to tacrine in Alzheimer's disease
36. Cholinesterase inhibitors in Parkinson's disease
37. Tacrine efficacy in Lewy body dementia
38. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
39. Donepezil for dementia with Lewy bodies: A case study
40. Donepezil for the treatment of psychosis in dementia with Lewy bodies
41. The use of cholinesterase inhibitors in dementia with Lewy bodies
42. Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial
43. Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: Findings from a placebo-controlled International Multicenter Study
44. Drug treatment in Lewy body dementia
45. The treatment of diffuse Lewy body disease: A pilot study
46. Treating behavioural and psychological signs in Alzheimer's disease
47. Comparison of risperidone and placebo for the psychosis and behavioural disturbances associated with dementia: A randomised, double-blind trial
48. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms in dementia
49. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
50. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
51. Risperidone for psychotic and behavioural symptoms in Lewy body dementia
52. Case report: The use of risperidone, an atypical neuroleptic in Lewy body disease
53. Olanzapine in dementia with Lewy bodies: A clinical study
54. Treatment of psychosis in patients with Parkinson's disease and dementia (Lewy body disease variant) with quetiapine
55. Neuropsychiatric aspects of Alzheimer's disease